NanoLogix Adds Noted Journalist Bill Scanlon to Provide Media Relations
24 March 2009 - 1:00AM
PR Newswire (US)
HUBBARD, Ohio, March 23 /PRNewswire-FirstCall/ -- NanoLogix
announces that veteran journalist Bill Scanlon has joined the
company to coordinate publicity in advance of major news. Scanlon's
addition to the staff marks a significant evolution in the
company's information flow to investors and media, and will aid in
the introduction of the public to NanoLogix products. Bill Scanlon
brings 25 years of experience in science, medical and business
writing to NanoLogix, including articles about rapid bio-detection.
For the past 18 years, he worked at the Rocky Mountain News, until
its closing last month. Among his numerous journalism honors are
awards for articles about particle physics, politics,
ultra-athletics, and medical transplants. His series on a hospital
cover-up recently won the Associated Press's annual First Amendment
Award. Bret T. Barnhizer, CEO stated: "We are fortunate to have
obtained Bill Scanlon's services. His addition comes at a time when
key elements of our business plan are converging. Enhanced public
relations will bring awareness of the capabilities of our BNP(TM)
test kit technology as we move the company from pure R&D and
into production." About NanoLogix NanoLogix is a biotechnology
company focused primarily on medical diagnostics. Its products
offer accelerated detection and identification of microorganisms
present in infectious and non-infectious human diseases, such as
tuberculosis, NTM, pneumonia, HIV/AIDS, cancer, cystic fibrosis,
anthrax, and plague. In addition to medical and homeland security
applications, NanoLogix technology is applicable in pharmaceutical,
industrial, veterinary and environmental testing. Patents granted
to NanoLogix can be used in the areas of applied microbiology, soil
microbiology and bioremediation, microbial physiology, molecular
biology, pharmacology, pharmaco-kinetics, antibiotic sensitivity,
stem-cell research, and bioreactor-based hydrogen generation." More
information on NanoLogix is available at:
http://www.nanologixinc.com/ This press release contains
statements, which may constitute "forward-looking statements"
within the meaning of the Securities Act of 1933 and the Securities
Exchange Act of 1934, as amended by the Private Securities
Litigation Reform Act of 1995. Those statements include statements
regarding the intent, belief or current expectations of NanoLogix,
Inc., and members of its management as well as the assumptions on
which such statements are based. Prospective investors are
cautioned that any such forward-looking statements are not
guarantees of future performance and involve risks and
uncertainties, and that actual results may differ materially from
those contemplated by such forward-looking statements. The Company
undertakes no obligation to update or revise forward-looking
statements to reflect changed assumptions, the occurrence of
unanticipated events or changes to future operating results.
Contact: Investor Relations Carol Surrena Telephone: 330-534-0800
E-mail: DATASOURCE: NanoLogix CONTACT: Investor Relations, Carol
Surrena, +1-330-534-0800, Web Site: http://www.nanologixinc.com/
Copyright